Enanta Pharmaceuticals Profit Margin

Enanta Pharmaceuticals (ENTA) currently reports a profit margin of -96.89% as of June 2026. That compares with -141.98% in the prior-year period — up 31.8% year over year. That is below the Healthcare sector average of 13.89%. Use the charts on this page to explore Enanta Pharmaceuticals's profit margin history and peer comparisons.

Enanta Pharmaceuticals's profit margin increased from -141.98% to -96.89% — a 31.8% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Enanta Pharmaceuticals's profit margin of -96.89% is lower than the Healthcare sector average of 13.89%. That is roughly 797.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Enanta Pharmaceuticals's current -96.89% should be judged against Healthcare norms (sector average: 13.89%) and against ENTA's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -96.89%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.89%. From there, open related valuation or income-statement pages for Enanta Pharmaceuticals, and consider following ENTA for alerts when major investors trade the stock.